Overview

This marketing authorisation for Fexeric has lapsed because it has not been marketed in the European Union in the three years following the granting of the authorisation.

български (BG) (314.37 KB - PDF)

View

español (ES) (250.12 KB - PDF)

View

čeština (CS) (302.38 KB - PDF)

View

dansk (DA) (248.78 KB - PDF)

View

Deutsch (DE) (252.04 KB - PDF)

View

eesti keel (ET) (245.44 KB - PDF)

View

ελληνικά (EL) (319.23 KB - PDF)

View

français (FR) (251.51 KB - PDF)

View

hrvatski (HR) (272.5 KB - PDF)

View

italiano (IT) (249.08 KB - PDF)

View

latviešu valoda (LV) (286.47 KB - PDF)

View

lietuvių kalba (LT) (276.98 KB - PDF)

View

magyar (HU) (293.07 KB - PDF)

View

Malti (MT) (301.08 KB - PDF)

View

Nederlands (NL) (249.38 KB - PDF)

View

polski (PL) (298.3 KB - PDF)

View

português (PT) (249.69 KB - PDF)

View

română (RO) (273.96 KB - PDF)

View

slovenčina (SK) (300.34 KB - PDF)

View

slovenščina (SL) (290.33 KB - PDF)

View

Suomi (FI) (248.57 KB - PDF)

View

svenska (SV) (246.33 KB - PDF)

View

Product information

български (BG) (937.09 KB - PDF)

View

español (ES) (462.93 KB - PDF)

View

čeština (CS) (787.3 KB - PDF)

View

dansk (DA) (465.89 KB - PDF)

View

Deutsch (DE) (490.13 KB - PDF)

View

eesti keel (ET) (468.75 KB - PDF)

View

ελληνικά (EL) (972.13 KB - PDF)

View

français (FR) (483.29 KB - PDF)

View

hrvatski (HR) (572.88 KB - PDF)

View

íslenska (IS) (471.06 KB - PDF)

View

italiano (IT) (476.59 KB - PDF)

View

latviešu valoda (LV) (785.64 KB - PDF)

View

lietuvių kalba (LT) (584.34 KB - PDF)

View

magyar (HU) (776.26 KB - PDF)

View

Malti (MT) (802.5 KB - PDF)

View

Nederlands (NL) (485.05 KB - PDF)

View

norsk (NO) (480.48 KB - PDF)

View

polski (PL) (793.89 KB - PDF)

View

português (PT) (461.27 KB - PDF)

View

română (RO) (588.89 KB - PDF)

View

slovenčina (SK) (770.04 KB - PDF)

View

slovenščina (SL) (728.68 KB - PDF)

View

Suomi (FI) (459.1 KB - PDF)

View

svenska (SV) (466.98 KB - PDF)

View

Latest procedure affecting product information: T/0015

09/09/2019

Globe icon

This medicine’s product information is available in all official EU languages.
Select 'available languages' to access the language you need.

Product information documents contain:

  • summary of product characteristics (annex I);
  • manufacturing authorisation holder responsible for batch release (annex IIA);
  • conditions of the marketing authorisation (annex IIB);
  • labelling (annex IIIA);
  • package leaflet (annex IIIB).

български (BG) (210.72 KB - PDF)

View

español (ES) (180.58 KB - PDF)

View

čeština (CS) (201.02 KB - PDF)

View

dansk (DA) (180.26 KB - PDF)

View

Deutsch (DE) (180.23 KB - PDF)

View

eesti keel (ET) (180.39 KB - PDF)

View

ελληνικά (EL) (211.9 KB - PDF)

View

français (FR) (180.33 KB - PDF)

View

hrvatski (HR) (193.25 KB - PDF)

View

íslenska (IS) (181.64 KB - PDF)

View

italiano (IT) (180.4 KB - PDF)

View

latviešu valoda (LV) (205.72 KB - PDF)

View

lietuvių kalba (LT) (196.89 KB - PDF)

View

magyar (HU) (200.44 KB - PDF)

View

Malti (MT) (201.34 KB - PDF)

View

Nederlands (NL) (180.21 KB - PDF)

View

norsk (NO) (181.79 KB - PDF)

View

polski (PL) (195.46 KB - PDF)

View

português (PT) (180.35 KB - PDF)

View

română (RO) (195.44 KB - PDF)

View

slovenčina (SK) (201.5 KB - PDF)

View

slovenščina (SL) (193.66 KB - PDF)

View

Suomi (FI) (180.12 KB - PDF)

View

svenska (SV) (180.33 KB - PDF)

View

Product details

Name of medicine
Fexeric
Active substance
ferric citrate coordination complex
International non-proprietary name (INN) or common name
ferric citrate coordination complex
Therapeutic area (MeSH)
  • Hyperphosphatemia
  • Renal Dialysis
Anatomical therapeutic chemical (ATC) code
V03AE

Therapeutic indication

Fexeric is indicated for the control of hyperphosphataemia in adult patients with chronic kidney disease (CKD).

Authorisation details

EMA product number
EMEA/H/C/003776
Marketing authorisation holder
Akebia Europe Limited

c/o Matheson
70 Sir John Rogerson’s Quay
Dublin 2
Ireland

Marketing authorisation issued
23/09/2015
Lapse of marketing authorisation
13/01/2020
Revision
2

Assessment history

This page was last updated on

Share this page